LifeMD (NASDAQ:LFMD) Announces Earnings Results, Beats Expectations By $0.03 EPS

LifeMD (NASDAQ:LFMD) released its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03, FiscalAI reports. The firm had revenue of $44.63 million for the quarter, compared to analysts’ expectations of $48.80 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.

Here are the key takeaways from LifeMD’s conference call:

• Third-quarter revenue was $44.6 million, below guidance of $48 million–$51 million and down about 7% year over year. LifeMD cut its 2026 revenue outlook to $188 million–$191 million from $205.5 million–$212.5 million and now expects an adjusted EBITDA loss of $10.6 million–$12.6 million.
• LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship branded GLP-1 medications through its pharmacy, potentially adding revenue and gross profit dollars from prescriptions it previously fulfilled through third parties. Management cautioned that gross margin percentage will decline as branded-drug revenue is reported on a gross basis.
• Management said customer acquisition cost fell 40% from its June peak, while the share of new Weight Management patients choosing multi-month plans rose from about 25% to 85%. Active subscribers were up 13% year over year and nearly flat sequentially despite a 34% quarter-over-quarter reduction in selling and marketing expense.
• The AT&T collaboration is live in 11 states, reaching about 29 million customers, with nationwide rollout expected in January; the company also plans to market its enterprise offering to employers. Management described these as lower-cost growth opportunities, but said they were not included in fourth-quarter guidance and will report traction as they scale.
• LifeMD ended the quarter with $21.9 million in cash and no debt, then closed a $12.5 million term loan to support working-capital needs. It is targeting a 25% reduction in operating expenses by the first quarter of 2027 and said it expects roughly 30% revenue and patient growth in 2027 on about the same fixed overhead.

LifeMD Stock Down 7.0%

Shares of LFMD stock traded down $0.12 during trading on Thursday, reaching $1.66. 1,629,100 shares of the company’s stock were exchanged, compared to its average volume of 876,691. LifeMD has a twelve month low of $1.60 and a twelve month high of $5.38. The firm’s fifty day moving average price is $2.62 and its 200-day moving average price is $3.58. The stock has a market capitalization of $79.77 million, a PE ratio of -33.09 and a beta of 2.19.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LFMD shares. Lake Street Capital set a $5.00 price target on shares of LifeMD in a research note on Thursday, August 6th. BTIG Research reduced their price objective on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Mizuho set a $7.00 price objective on shares of LifeMD in a research note on Thursday, August 6th. Weiss Ratings restated a “sell (d)” rating on shares of LifeMD in a report on Monday, November 2nd. Finally, Wall Street Zen downgraded LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, LifeMD has an average rating of “Moderate Buy” and an average price target of $7.57.

LifeMD Company Profile

LifeMD, Inc. is a direct-to-consumer telehealth company that provides virtual medical care, prescription treatments and related health services through its digital platform. The company connects patients with licensed health care providers for online consultations, ongoing care and, when clinically appropriate, prescription medications. Its services include virtual primary care and programs focused on areas such as weight management, men’s health, women’s health, dermatology and chronic-care support.